At this point I think it's silly to believe the GOP won't bend to his every whim until proven otherwise.
RFK Jr wants to end the development of new cancer treatments, alzheimers and more
- Thread starter Chishawk1425
- Start date
“The president elect deserves to bring in the people he thinks will help him succeed”.
That doesn't mean that every President gets every nomination approved. Either way, he hasn't even been inaugurated and won't be for a couple months. One thing he has done successfully is live rent-free in a lot of the left's heads by successfully trolling it. There are so many nominations that won't make it through right now that nobody can even pick a single one to cry loudest about.
Which one is your favorite? The white nationalist? The dog shooter? The sexual predator? Brain worm?
Overwhelmingly, the president's nominations get approved at least to start his term in office.
Frankly, I expect all of his nominations to go through - we just have no evidence that GOP tough talk now will translate into enough No votes come 2025.
Conclusions: This review finds that all of the nine currently US-approved dyes raise health concerns of varying degrees. Red 3 causes cancer in animals, and there is evidence that several other dyes also are carcinogenic. Three dyes (Red 40, Yellow 5, and Yellow 6) have been found to be contaminated with benzidine or other carcinogens. At least four dyes (Blue 1, Red 40, Yellow 5, and Yellow 6) cause hypersensitivity reactions. Numerous microbiological and rodent studies of Yellow 5 were positive for genotoxicity.
(nih.gov)
Maybe because that’s not why people are upset about his pic.
So why do you oppose submitting vaccines to the same double blind placebo trials we use for other medicine.
What's the logic behind that?
I've stated this a half dozen times now.
When they had the chance, and after they were all enraged by the 1/6 insurrection (which many publicly blamed Trump for), they refuse to impeach and convict him - which would have ended this.
Many went off-record claiming they could not vote against him, because they feared for their own livelihoods and their own families. This was when he was not in power, and had no influence over the federal government and DOJ.
What makes anyone think these same folks who were too chickenshit to do the right thing back in 2021 will somehow "grow a pair" in 2025 and onward?
Eric Topol (@erictopol.bsky.social)
A whopping (~90%) reduction of progression to Type 2 diabetes with tirzepatide (GLP-1 drug, dual receptor) vs placebo in a randomized trial of >2,500 participants with obesity, absolute reduction of 10/100 treated t.co/71hKD8v7Y2
bsky.app
Is "90% reduction" considered "good" in medicine, for prevention of a major, debilitating health condition?
Asking for a friend...
Depends on whether or not you are a 58 yr old nurse from Scotland…or WERE a 58 yr old nurse. 😵
Eric Topol (@erictopol.bsky.social)
A whopping (~90%) reduction of progression to Type 2 diabetes with tirzepatide (GLP-1 drug, dual receptor) vs placebo in a randomized trial of >2,500 participants with obesity, absolute reduction of 10/100 treated t.co/71hKD8v7Y2
Is "90% reduction" considered "good" in medicine, for prevention of a major, debilitating health condition?
Asking for a friend...
Nurse's death linked to weight-loss drug Mounjaro approved on NHS
Susan McGowan from North Lanarkshire died two weeks after taking the drug tirzepatide, brand name Mounjaro.
www.bbc.com
And LMFAO at a ‘study’ for an Eli Lilly drug that has six Eli Lilly employees listed as authors.
In both sexes of rats, tirzepatide caused a dose-dependent and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) in a 2-year study at clinically relevant plasma exposures [see Nonclinical Toxicology (13.1)]. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.
MOUNJARO is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2. Counsel patients regarding the potential risk for MTC with the use of MOUNJARO and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness).
Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with MOUNJARO. Such monitoring may increase the risk of unnecessary procedures, due to the low test specificity for serum calcitonin and a high background incidence of thyroid disease. Significantly elevated serum calcitonin values may indicate MTC and patients with MTC usually have calcitonin values >50 ng/L. If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated.
5.2 Pancreatitis
Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists.
In clinical studies, 14 events of acute pancreatitis were confirmed by adjudication in 13 MOUNJARO-treated patients (0.23 patients per 100 years of exposure) versus 3 events in 3 comparator-treated patients (0.11 patients per 100 years of exposure). MOUNJARO has not been studied in patients with a prior history of pancreatitis. It is unknown if patients with a history of pancreatitis are at higher risk for development of pancreatitis on MOUNJARO.
After initiation of MOUNJARO, observe patients carefully for signs and symptoms of pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back and which may or may not be accompanied by vomiting). If pancreatitis is suspected, discontinue MOUNJARO and initiate appropriate management.
5.3 Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin
Patients receiving MOUNJARO in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia [see Adverse Reactions (6.1), Drug Interactions (7.1)].
The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.
5.4 Hypersensitivity Reactions
Hypersensitivity reactions have been reported with MOUNJARO in clinical trials (e.g., urticaria and eczema) and were sometimes severe. If hypersensitivity reactions occur, discontinue use of MOUNJARO; treat promptly per standard of care, and monitor until signs and symptoms resolve. Do not use in patients with a previous serious hypersensitivity reaction to tirzepatide or any of the excipients in MOUNJARO [see Contraindications (4)].
Anaphylaxis and angioedema have been reported with GLP-1 receptor agonists. Use caution in patients with a history of angioedema or anaphylaxis with a GLP-1 receptor agonist because it is unknown whether such patients will be predisposed to these reactions with MOUNJARO.
5.5 Acute Kidney Injury
MOUNJARO has been associated with gastrointestinal adverse reactions, which include nausea, vomiting, and diarrhea [see Adverse Reactions (6.1)]. These events may lead to dehydration, which if severe could cause acute kidney injury.
In patients treated with GLP-1 receptor agonists, there have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis. Some of these events have been reported in patients without known underlying renal disease. A majority of the reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration. Monitor renal function when initiating or escalating doses of MOUNJARO in patients with renal impairment reporting severe gastrointestinal adverse reactions.
5.6 Severe Gastrointestinal Disease
Use of MOUNJARO has been associated with gastrointestinal adverse reactions, sometimes severe [see Adverse Reactions 6.1]. MOUNJARO has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis, and is therefore not recommended in these patients.
5.7 Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy
Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. MOUNJARO has not been studied in patients with non-proliferative diabetic retinopathy requiring acute therapy, proliferative diabetic retinopathy, or diabetic macular edema. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.
5.8 Acute Gallbladder Disease
Acute events of gallbladder disease such as cholelithiasis or cholecystitis have been reported in GLP-1 receptor agonist trials and postmarketing.
In MOUNJARO placebo-controlled clinical trials, acute gallbladder disease (cholelithiasis, biliary colic, and cholecystectomy) was reported by 0.6% of MOUNJARO-treated patients and 0% of placebo-treated patients. If cholelithiasis is suspected, gallbladder diagnostic studies and appropriate clinical follow-up are indicated.
6 ADVERSE REACTIONS
The following serious adverse reactions are described below or elsewhere in the prescribing information:
• Risk of Thyroid C-cell Tumors [see Warnings and Precautions (5.1)]
• Pancreatitis [see Warnings and Precautions (5.2)]
• Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.3)]
• Hypersensitivity [see Warnings and Precautions (5.4)]
• Acute Kidney Injury [see Warnings and Precautions (5.5)] (fda.gov)
More lies from the left, your scare tactics don't work anymore.
has this been answered elsewhere? if not could someone take a shot?
Seminole he wants to stop vaccines, new drug research everything, are you really stupid enough to believe or support this? He’s a f*ing who has no business managing that department.
The vaccines have had more research than almost any other medication.
Do you support submitting vaccines to the same double blind placebo trials we use for other medicine?
If not, why not?
Sure no worries on my end. Regarding the flu vaccines you really going to need to do this every year?
Depends on whether or not you are a 58 yr old nurse from Scotland…or WERE a 58 yr old nurse. 😵
Nurse's death linked to weight-loss drug Mounjaro approved on NHS
Susan McGowan from North Lanarkshire died two weeks after taking the drug tirzepatide, brand name Mounjaro.
And LMFAO at a ‘study’ for an Eli Lilly drug that has six Eli Lilly employees listed as authors.
In both sexes of rats, tirzepatide caused a dose-dependent and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) in a 2-year study at clinically relevant plasma exposures [see Nonclinical Toxicology (13.1)]. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.
MOUNJARO is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2. Counsel patients regarding the potential risk for MTC with the use of MOUNJARO and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness).
Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with MOUNJARO. Such monitoring may increase the risk of unnecessary procedures, due to the low test specificity for serum calcitonin and a high background incidence of thyroid disease. Significantly elevated serum calcitonin values may indicate MTC and patients with MTC usually have calcitonin values >50 ng/L. If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated.
5.2 Pancreatitis
Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists.
In clinical studies, 14 events of acute pancreatitis were confirmed by adjudication in 13 MOUNJARO-treated patients (0.23 patients per 100 years of exposure) versus 3 events in 3 comparator-treated patients (0.11 patients per 100 years of exposure). MOUNJARO has not been studied in patients with a prior history of pancreatitis. It is unknown if patients with a history of pancreatitis are at higher risk for development of pancreatitis on MOUNJARO.
After initiation of MOUNJARO, observe patients carefully for signs and symptoms of pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back and which may or may not be accompanied by vomiting). If pancreatitis is suspected, discontinue MOUNJARO and initiate appropriate management.
5.3 Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin
Patients receiving MOUNJARO in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia [see Adverse Reactions (6.1), Drug Interactions (7.1)].
The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.
5.4 Hypersensitivity Reactions
Hypersensitivity reactions have been reported with MOUNJARO in clinical trials (e.g., urticaria and eczema) and were sometimes severe. If hypersensitivity reactions occur, discontinue use of MOUNJARO; treat promptly per standard of care, and monitor until signs and symptoms resolve. Do not use in patients with a previous serious hypersensitivity reaction to tirzepatide or any of the excipients in MOUNJARO [see Contraindications (4)].
Anaphylaxis and angioedema have been reported with GLP-1 receptor agonists. Use caution in patients with a history of angioedema or anaphylaxis with a GLP-1 receptor agonist because it is unknown whether such patients will be predisposed to these reactions with MOUNJARO.
5.5 Acute Kidney Injury
MOUNJARO has been associated with gastrointestinal adverse reactions, which include nausea, vomiting, and diarrhea [see Adverse Reactions (6.1)]. These events may lead to dehydration, which if severe could cause acute kidney injury.
In patients treated with GLP-1 receptor agonists, there have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis. Some of these events have been reported in patients without known underlying renal disease. A majority of the reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration. Monitor renal function when initiating or escalating doses of MOUNJARO in patients with renal impairment reporting severe gastrointestinal adverse reactions.
5.6 Severe Gastrointestinal Disease
Use of MOUNJARO has been associated with gastrointestinal adverse reactions, sometimes severe [see Adverse Reactions 6.1]. MOUNJARO has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis, and is therefore not recommended in these patients.
5.7 Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy
Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. MOUNJARO has not been studied in patients with non-proliferative diabetic retinopathy requiring acute therapy, proliferative diabetic retinopathy, or diabetic macular edema. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.
5.8 Acute Gallbladder Disease
Acute events of gallbladder disease such as cholelithiasis or cholecystitis have been reported in GLP-1 receptor agonist trials and postmarketing.
In MOUNJARO placebo-controlled clinical trials, acute gallbladder disease (cholelithiasis, biliary colic, and cholecystectomy) was reported by 0.6% of MOUNJARO-treated patients and 0% of placebo-treated patients. If cholelithiasis is suspected, gallbladder diagnostic studies and appropriate clinical follow-up are indicated.
6 ADVERSE REACTIONS
The following serious adverse reactions are described below or elsewhere in the prescribing information:
• Risk of Thyroid C-cell Tumors [see Warnings and Precautions (5.1)]
• Pancreatitis [see Warnings and Precautions (5.2)]
• Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.3)]
• Hypersensitivity [see Warnings and Precautions (5.4)]
• Acute Kidney Injury [see Warnings and Precautions (5.5)] (fda.gov)
Here's the author's list from the study I linked for you.
Email them for your silly questions
From the Section of Endocrinology and Metabolism, Department of Medicine, and Section of Pediatric Endocrinology, Department of Pediatrics, Yale Obesity Research Center (Y-Weight), Yale School of Medicine, New Haven, CT (A.M.J.); Diabetes Complications Research Centre, University College Dublin, Dublin (C.W.R.); Eli Lilly, Indianapolis (A.S., S.Z., R.B., M.C.B., N.N.A., I.J.); Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York (L.J.A.); Hospital 9 de Julho, São Paulo (B.H.); University of Toronto and Wharton Weight Management Clinic — both in Toronto (S.W.); the Department of Cardiovascular and Metabolic Medicine, University of Liverpool, Liverpool, United Kingdom (J.P.H.W.); and University of Colorado School of Medicine, Aurora (L.P.).
My post in another thread
From someone who studies Covid, Long Covid and vaccines:
"I tell anyone who asks that I am not afraid of COVID, but I am terrified of Long COVID. So I am grateful to the authors of this New England Journal of Medicine study for quantifying the risk of Long COVID and the reduction in incidence, thanks in large part to vaccination."
-Dr. Lisa Sanders, Medical Director of Yale's Long Covid Multidisciplinary Care Center
From someone who studies Covid, Long Covid and vaccines:
"I tell anyone who asks that I am not afraid of COVID, but I am terrified of Long COVID. So I am grateful to the authors of this New England Journal of Medicine study for quantifying the risk of Long COVID and the reduction in incidence, thanks in large part to vaccination."
-Dr. Lisa Sanders, Medical Director of Yale's Long Covid Multidisciplinary Care Center
Fauci called him a liar, then finally the lawyers admitted RFK Jr. was right and it was Fauci who lied.
Instead of acknowledge that reality you pivot to the messenger of that truth.
Weak sauce.
You're totally misguided on this subject yet how could we expect anything less from someone like you with your head up your ass 24/7.
I don’t have any questions, silly or otherwise.
The dead nurse, the black box warnings and the huge conflicts of interest with the Eli Lilly employees tell me everything I need to know.
You simply want to regurgitate disinformation and not learn anything from actual physicians and scientists.
BAU
A news article from the BBC, the author affiliation(s) from a study that YOU linked and an FDA-supplied insert that’s absolutely loaded with dire adverse event warnings is ‘disinformation’?
P’soff, Fluffer Boy.
You shouldn’t trust in-your-face conflicts of interest by pharmaceutical employees trying to convince you their dangerous products are safe.
